AGENCIES, New Delhi: Bharat BioTech’s Covid-19 vaccine, Covaxin, has become the second vaccine to secure recommendation for restricted emergency use from a government-appointed expert panel in India. This comes a day after the panel made a similar recommendation for Covishield, the vaccine developed by Oxford University and AstraZenca.
An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on Saturday made the recommendation for Covaxin saying it should be granted permission for “restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains”.
However, a final decision on whether these two vaccines should be given emergency use approval in India will be taken by the Drugs Controller General of India (DCGI).
The panel’s recommendation for emergency use for the two vaccines paves the way for rollout of Covid-19 vaccines in India.
Meanwhile, apart from the recommendations for Covaxin and Covishield, the Subject Expert Committee (SEC) of CDSCO also recommended Phase-III trials of the vaccine candidate that is being developed by Cadila Healthcare Ltd.
On Saturday, all states and UTs held a dry-run for Covid-19 vaccination. Union Health Minister Harsh Vardhan appealed to people not to be misguided by rumours and disinformation regarding the safety and efficacy of the coronavirus vaccine.
The health minister said free vaccine would be provided in the first phase to the most prioritised beneficiaries, including one crore healthcare and two crore frontline workers.
